IL166511A0 - Enos mutants useful for gene therapy - Google Patents

Enos mutants useful for gene therapy

Info

Publication number
IL166511A0
IL166511A0 IL16651105A IL16651105A IL166511A0 IL 166511 A0 IL166511 A0 IL 166511A0 IL 16651105 A IL16651105 A IL 16651105A IL 16651105 A IL16651105 A IL 16651105A IL 166511 A0 IL166511 A0 IL 166511A0
Authority
IL
Israel
Prior art keywords
gene therapy
mutants useful
enos
enos mutants
useful
Prior art date
Application number
IL16651105A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL166511A0 publication Critical patent/IL166511A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
IL16651105A 2002-08-16 2005-01-26 Enos mutants useful for gene therapy IL166511A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40363802P 2002-08-16 2002-08-16
PCT/US2003/025745 WO2004016764A2 (en) 2002-08-16 2003-08-15 eNOS MUTANTS USEFUL FOR GENE THERAPY

Publications (1)

Publication Number Publication Date
IL166511A0 true IL166511A0 (en) 2006-01-15

Family

ID=31888260

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16651105A IL166511A0 (en) 2002-08-16 2005-01-26 Enos mutants useful for gene therapy

Country Status (15)

Country Link
US (1) US20040096881A1 (xx)
EP (1) EP1553973A4 (xx)
JP (1) JP2005535345A (xx)
KR (1) KR20050042788A (xx)
CN (1) CN1691958A (xx)
AU (1) AU2003265461A1 (xx)
BR (1) BR0313511A (xx)
CA (1) CA2494847A1 (xx)
IL (1) IL166511A0 (xx)
MX (1) MXPA05001906A (xx)
NO (1) NO20051347L (xx)
PL (1) PL375219A1 (xx)
RU (1) RU2005107410A (xx)
WO (1) WO2004016764A2 (xx)
ZA (1) ZA200502183B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074448A1 (en) * 2003-03-24 2005-04-07 The Curator Sof The University Of Missouri Method of treatment of endothelial dysfunction and engineered proteins for same
CA2545584C (en) 2003-11-17 2012-10-23 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
US8615368B2 (en) 2005-03-10 2013-12-24 Gen-Probe Incorporated Method for determining the amount of an analyte in a sample
EP1897016B1 (en) * 2005-06-22 2012-08-01 Gen-Probe Incorporated Method and algorithm for quantifying polynucleotides
US10550178B2 (en) * 2010-03-18 2020-02-04 Srikanth Vedamoorthy Antibodies for detecting redox modulated proteins
US9439978B2 (en) 2011-09-29 2016-09-13 University Of South Florida Multilayered magnetic micelle compositions and methods for their use
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US9782494B2 (en) 2012-02-23 2017-10-10 University Of South Florida Methods of using multilayer magnetic micelle compositions
WO2013154771A1 (en) * 2012-04-12 2013-10-17 Georgia Regents University Redox-resistant nitric oxide synthase
EP3163481B1 (en) * 2014-06-25 2019-05-01 Japan Science And Technology Agency Device, method and program for predicting mutant capable of thermally stabilizing membrane protein
CN107802826B (zh) * 2017-10-26 2020-02-18 首都医科大学宣武医院 eNOS突变体在促进血管生成中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK14692001A3 (sk) * 1999-04-16 2002-09-10 Yale University Izolovaná molekula nukleovej kyseliny, izolovaný NOS polypeptid, spôsob stimulácie, spôsob liečby, spôsob identifikácie a nehumánne transgénne zviera
US6620616B1 (en) * 2000-09-13 2003-09-16 The Cleveland Clinic Foundation Nucleic acids encoding nitric oxide synthase variants

Also Published As

Publication number Publication date
WO2004016764A3 (en) 2005-05-19
BR0313511A (pt) 2006-06-13
NO20051347L (no) 2005-04-28
EP1553973A4 (en) 2006-03-01
KR20050042788A (ko) 2005-05-10
WO2004016764A2 (en) 2004-02-26
ZA200502183B (en) 2006-09-27
US20040096881A1 (en) 2004-05-20
CN1691958A (zh) 2005-11-02
RU2005107410A (ru) 2006-01-20
PL375219A1 (en) 2005-11-28
EP1553973A2 (en) 2005-07-20
CA2494847A1 (en) 2004-02-26
JP2005535345A (ja) 2005-11-24
AU2003265461A1 (en) 2004-03-03
MXPA05001906A (es) 2005-04-28

Similar Documents

Publication Publication Date Title
IL166511A0 (en) Enos mutants useful for gene therapy
GB0206033D0 (en) Compounds useful in therapy
AU2003209226A1 (en) Adiponectin gene therapy
EP1490074A4 (en) MIXED CELL GENE THERAPY
PL373086A1 (en) Allergen mutants
AU2003277910A1 (en) Ocular gene therapy
AU2003247005A1 (en) Therapy combination
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
ZA200707236B (en) Microorganisms for therapy
AU2003249054A8 (en) Neuronal gene expression patterns
GB0327384D0 (en) Gene therapy
EP1472498A4 (en) DURATION PROCESS FURNACE
IL166362A0 (en) Gene therapy for critical limb ischemia with wild type or mutant enos
GB0213848D0 (en) Furnace
GB0210741D0 (en) Methods of therapy
AU2003285079A1 (en) Neurostimulation therapy manipulation
AU2003302893A1 (en) METHODS FOR SUSTAINING eNOS ACTIVITY
GB2385333B (en) Plate treatment
EP1569928A4 (en) THERAPEUTIC COMPOUNDS AND METHOD
GB0207299D0 (en) Stem cell therapy
GB2390110B (en) Access apparatus
AU2003231937A8 (en) Therapeutic methods
GB0201624D0 (en) Furnace
AU2003292095A1 (en) Overhead heating
GB0213383D0 (en) Therapeutic conditions